These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10946780)

  • 1. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression.
    Rasaiah SB; Light JA; Sasaki TM; Currier CB
    Clin Transplant; 2000 Aug; 14(4 Pt 2):409-12. PubMed ID: 10946780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
    Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
    Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.
    Noël C; Abramowicz D; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Hazzan M
    J Am Soc Nephrol; 2009 Jun; 20(6):1385-92. PubMed ID: 19470677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymoglobulin induction decreases rejection in solitary pancreas transplantation.
    Stegall MD; Kim DY; Prieto M; Cohen AJ; Griffin MD; Schwab TR; Nyberg SL; Velosa JA; Gloor JM; Innocenti F; Bohorquez H; Dean PG; Carpenter HA; Leontovich ON; Sterioff S; Larson TS
    Transplantation; 2001 Nov; 72(10):1671-5. PubMed ID: 11726830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
    Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
    Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
    Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
    Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
    Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results.
    Schulz T; Flecken M; Kapischke M; Busing M
    Transplant Proc; 2005 May; 37(4):1818-20. PubMed ID: 15919476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous kidney-pancreas transplantation without antilymphocyte induction.
    Reddy KS; Stratta RJ; Shokouh-Amiri H; Alloway R; Somerville T; Egidi MF; Gaber LW; Gaber AO
    Transplantation; 2000 Jan; 69(1):49-54. PubMed ID: 10653379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
    Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
    Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A; Grego K; Bren AF
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
    Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR; Faulds D
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and treatment of rejection after simultaneous pancreas-kidney transplantation.
    Yang L; Liu YF; Liu SR; Wu G; Zhang JL; Meng YM; Shong SW; Li GC
    Chin Med Sci J; 2005 Sep; 20(3):210-3. PubMed ID: 16261897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
    Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J
    J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.